InnaVirVax SA - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 23 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

InnaVirVax SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'InnaVirVax SA - Product Pipeline Review - 2014', provides an overview of the InnaVirVax SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InnaVirVax SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of InnaVirVax SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of InnaVirVax SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the InnaVirVax SA's pipeline products

Reasons to buy

- Evaluate InnaVirVax SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of InnaVirVax SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the InnaVirVax SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of InnaVirVax SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of InnaVirVax SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of InnaVirVax SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
InnaVirVax SA Snapshot 4
InnaVirVax SA Overview 4
Key Information 4
Key Facts 4
InnaVirVax SA - Research and Development Overview 5
Key Therapeutic Areas 5
InnaVirVax SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
InnaVirVax SA - Pipeline Products Glance 9
InnaVirVax SA - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
InnaVirVax SA - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
InnaVirVax SA - Drug Profiles 12
VAC-3S 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
VAC-02 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
STOP-3S 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
VAC-03 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
InnaVirVax SA - Pipeline Analysis 17
InnaVirVax SA - Pipeline Products by Route of Administration 17
InnaVirVax SA - Pipeline Products by Molecule Type 18
InnaVirVax SA - Recent Pipeline Updates 19
InnaVirVax SA - Dormant Projects 20
InnaVirVax SA - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables
InnaVirVax SA, Key Information 4
InnaVirVax SA, Key Facts 4
InnaVirVax SA - Pipeline by Indication, 2014 6
InnaVirVax SA - Pipeline by Stage of Development, 2014 7
InnaVirVax SA - Monotherapy Products in Pipeline, 2014 8
InnaVirVax SA - Phase II, 2014 9
InnaVirVax SA - Preclinical, 2014 10
InnaVirVax SA - Discovery, 2014 11
InnaVirVax SA - Pipeline by Route of Administration, 2014 17
InnaVirVax SA - Pipeline by Molecule Type, 2014 18
InnaVirVax SA - Recent Pipeline Updates, 2014 19
InnaVirVax SA - Dormant Developmental Projects,2014 20